Eidos rejects BridgeBio bid for shares

|About: Eidos Therapeutics, Inc. (EIDX)|By:, SA News Editor

The board of Eidos Therapeutics (NASDAQ:EIDX) unanimously rejects an offer from BridgeBio Pharma (NASDAQ:BBIO) to acquire the remaining shares that it does not currently own (~2/3 of EIDX's outstanding stock) at a fixed ratio of 1.30 BBIO shares for each EIDX share. The board considers the bid "inadequate" and "not in the best interests of [its] minority shareholders."

Subscribe for full text news in your inbox